KIMS Q1 FY26 Earnings Results

Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities. Presenting below are its Q1 FY26 earnings results.

 

Q1 FY26 Earnings Results

• Total Revenue: ₹872 crores, up 26.7% YoY from ₹693.3 crores and up 9.6% QoQ from ₹801.4 crores (Q4 FY25).

• EBITDA: ₹200.0 crores, up 8.5% YoY, margin at 22.7% (Q1 FY25: 26.6%; Q4 FY25: 25.3%).

• Profit After Tax (PAT): ₹85 crores, down 10.5% QoQ from ₹95.0 crores (Q1 FY25: ₹95.0 crores; Q4 FY25: ₹106.0 crores).

• Consolidated EPS: ₹1.96, down 9.2% YoY.

• PAT Margin: 9.7% (Q1 FY25: 13.7%).

• ARPOB (Average Revenue Per Occupied Bed): ₹43,011, up 11.8% YoY and up 3.2% QoQ.

• Consolidated Occupancy: 48.8% (down 100bps YoY, up 80bps QoQ).

• Inpatient Volumes: up 15.3% YoY / 6.2% QoQ; Outpatient Volumes: up 19.3% YoY / 7.2% QoQ.

• Cash and Cash Equivalents: ₹70 crores as of Q1 FY26.

• Expansion: Multiple new hospitals—in Thane, Nashik, Kollam—added, with Bangalore launches expected in Q2; 1,900+ beds in pipeline.

 

Management Commentary & Strategic Decisions

• CMD Dr. B Bhaskar Rao remarked on “robust performance” despite a seasonally lean quarter and margin compression from ramp-up in new units.

• Margin dilution primarily due to pre-operative and ramp-up losses in new hospitals (Thane, Nashik, Kollam); most are expected to break even within FY26.

• Management expects 22-25% EBITDA margin for FY26 and targets ARPOB growth of 4–5% annually, driving overall growth with continued network expansion.

• Strategic focus on new asset-light O&M deals, furthering penetration in high-growth micro-markets, and scaling up insurance/TPA empanelments to lift occupancy.

• Mature clusters (Telangana, Andhra Pradesh) maintained high profitability and margins, cushioning margin impact of new geographies.

 

 

Q4 FY25 Earnings Results

• Total Revenue: ₹797 crores, up 25.7% YoY.

• EBITDA: ₹203.0 crores, margin 25.3%.

• PAT: ₹106 crores, up 47% YoY.

• ARPOB: ₹41,469, up 21% YoY.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.